COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
NIH staff guidance on coronavirus (NIH Only)

Other NIH Programs for Translational Neuroscience

Funding for High Throughput Screening

Solicitation of Assays for HTS to Discover Chemical Probes

Funding for Medicinal Chemistry (Hit-to-Lead)

Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes

Funding for Preclinical Proof-of-Concept

Drug Discovery for Nervous System Disorders

Funding for Preclinical/Clinical Development

National Cooperative Drug Discovery/Development Groups (NCDDG)

Regulatory Affairs Assistance for Medications Development

  • Support: Provides consultation and advice on regulatory requirements
  • Participating Institute: NIDA
  • To apply: Contact Robert Walsh, R.A.C.

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (STTR)

  • Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.

  • Participating Institute: NIAAA

  • To apply: PAR-18-580 (UT2 - Clinical Trial Optional)

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (SBIR)

  • Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.

  • Participating Institute: NIAAA
  • To apply: PAR-18-578 (U44 - Clinical Trial Optional)

Strategic Alliances for Medications Development to Treat Substance-Use Disorders

  • Support: Up to 3 years of funding, includes discovery, development, and clinical trials. $3M per year with expectation of matching funds

  • Participating Institute: NIDA

  • To apply: PAR-19-318 (R01)

Grand Opportunities in Medications Development for Substance-Use Disorders

  • Support: Up to 3 years of funding, milestone-driven, up to $5M per year

  • Participating Institute: NIDA

  • To apply: PAR-19-327 (U01)

Alzheimer's Drug-Development Program

  • Support: Up to 5 years of funding, milestone-driven, up to $1M per year

  • Participating Institute: NIA

  • To apply: PAR-18-820 (U01)

Services

Services Services for Pharmacology

Epilepsy Therapy Screening Program (ETSP)

  • Support: Screens compounds in animal seizure models
  • To apply: Contact John Kehne, Ph.D.

Addiction Treatment Discovery Program (ATDP)

  • Support: Screens compounds in animal models of addiction
  • To apply: Contact David White, Ph.D., (301) 443-8889

NIMH Psychoactive Drug Screening Program (PDSP)

  • Support: Screens novel psychoactive compounds for pharmacological and functional activity at cloned human or rodent CNS receptors, channels, and transporters.
  • To apply: Contact Jamie Driscoll, (301) 443-5288

Services for Toxicology

Bridging Interventional Development Gaps (BrIDGs)

NIMH Toxicological Evaluation of Novel Ligands Program

  • Support: Provides toxicology, safety, in vitro ADME, and pharmacokinetic assessment of promising, target-selective compounds for use as imaging ligands and novel psychoactive drugs.
  • To apply: Contact Jamie Driscoll, (301) 443-5288

NIDA Toxicology Program

  • Support: Provides IND-directed toxicology services for substance abuse indications.
  • To apply: Contact Nathan M. Appel, Ph.D., (301) 443-8475

Services for Chemistry

Bridging Interventional Development Gaps (BrIDGs)

NIDA Drug Supply Program

  • Support: Provides chemicals and research probes that are either unavailable, difficult to obtain, or very expensive to buy to researchers, including marijuana plant materials, cannabinoids, opioids, stimulants, sedatives, hypnotics, standardized research E-Cigarettes and nicotine research c, etc. Also provides analytical services for the analysis of researchers’ experimental samples.
  • To apply: Contact: Richard Kline, Ph.D., (301) 443-5280

NIMH Chemical Synthesis and Drug Supply Program

  • Support: Synthesizes and distributes novel research chemicals, psychoactive drugs, and compounds unavailable from commercial sources. Also supports radiosynthesis, medicinal chemistry, and GMP synthesis for clinical studies.
  • To apply: Contact Jamie Driscoll, (301) 443-5288

NIDA Chemistry and Pharmaceutics Branch

  • Support: Medicinal chemistry, analytical chemistry, metabolism, pharmacokinetics and pharmacodynamics, pharmacogenetics and pharmaceutics/formulation development aimed at the design, evaluation and development of medications for the treatment of drug addiction
  • To apply: Contact Rik Klein, (301)-827-5243, rkline@nida.nih.gov